ReviewCirculation2022
Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association: Endorsed by the American Society of Transplantation.
Review in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome.Journal of the American Society of Nephrology : JASN · 2026Guideline
- AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation.Hepatology (Baltimore, Md.) · 2026Guideline
- Class 1 Indications for Coronary Revascularization Identified in Prekidney Transplant Screening.Journal of the American Society of Nephrology : JASN · 2026Pooled it
- Cardiovascular Complications of Chronic Liver Disease.Circulation · 2026Review
- Pharmacologic Stress Myocardial Perfusion Imaging with SPECT and PET in Liver Transplant Candidates: Physiologic Limitations, Current Evidence, and Future Directions.Current cardiology reports · 2026Review
- Association of Moderate Coronary Artery Disease Burden With Major Adverse Cardiovascular Events Following Kidney Transplantation.Transplantation proceedings · 2026Article
- Impact of Preoperative Cardiac Screening Modality on Cardiovascular Outcomes After Liver Transplantation.Clinical transplantation · 2026Article
- Distinct prognostic trajectories of heart failure phenotypes following kidney transplantation.ESC heart failure · 2026Article
- Cardiac Comorbidity Burden and Post-Liver Transplant Outcomes: A Propensity-Matched Multicenter Analysis.Journal of clinical medicine · 2026Article
- Update in Perioperative Ischemic Workup: Integrating 2024 AHA/ACC Guidelines and Contemporary Evidence.Journal of cardiovascular development and disease · 2026Review
- Targeting LDL Across the Whole Spectrum of Chronic Kidney Disease: From Pathophysiology to Novel Treatments.Current atherosclerosis reports · 2026Review
- The Pre-Kidney Transplant Cardiovascular Evaluation: A Narrative Review of Current Scientific Statements and Consensus Documents.Cardiology and therapy · 2026Review
- New kidneys, old risks: cardiovascular challenges after transplantation.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- Association of Pre-Transplant Stress Echocardiography Findings in 354 Kidney Transplant Recipients With Posttransplant Major Adverse Cardiovascular Events.Annals of transplantation · 2026Article
- The Clinical Role and Impact of Dobutamine Stress Echocardiography in Liver Transplantation.Echocardiography (Mount Kisco, N.Y.) · 2026Article
- Association of left atrial volume and function parameters with cardiovascular outcomes following kidney transplantation.Cardiovascular ultrasound · 2026Article
- Article
- Expanding aorto-iliac calcification quantification in kidney transplant recipients: prognostic implications for survival and renal function.Abdominal radiology (New York) · 2026Article
- Steatotic liver disease and liver transplantation: Candidate selection and post-transplant management.JHEP reports : innovation in hepatology · 2026Review
- Major adverse cardiovascular events after liver transplantation: a population cohort analysis of English transplant centres.EClinicalMedicine · 2026Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Coronary heart disease is an important source of mortality and morbidity among kidney transplantation and liver transplantation candidates and recipients and is driven by traditional and nontraditional risk factors related to end-stage organ disease. In this scientific statement, we review evidence from the past decade related to coronary heart disease screening and management for kidney and liver transplantation candidates. Coronary heart disease screening in asymptomatic kidney and liver transplantation candidates has not been demonstrated to improve outcomes but is common in practice. Risk stratification algorithms based on the presence or absence of clinical risk factors and physical performance have been proposed, but a high proportion of candidates still meet criteria for screening tests. We suggest new approaches to pretransplantation evaluation grounded on the presence or absence of known coronary heart disease and cardiac symptoms and emphasize multidisciplinary engagement, including involvement of a dedicated cardiologist. Noninvasive functional screening methods such as stress echocardiography and myocardial perfusion scintigraphy have limited accuracy, and newer noninvasive modalities, especially cardiac computed tomography-based tests, are promising alternatives. Emerging evidence such as results of the 2020 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease trial emphasizes the vital importance of guideline-directed medical therapy in managing diagnosed coronary heart disease and further questions the value of revascularization among asymptomatic kidney transplantation candidates. Optimizing strategies to disseminate and implement best practices for medical management in the broader end-stage organ disease population should be prioritized to improve cardiovascular outcomes in these populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.